Timothy Kwok1, Jason Leung2, Elizabeth Barrett-Connor3. 1. Department of Medicine & Therapeutics, the Chinese University of Hong Kong. 2. Jockey Club Centre for Osteoporosis Care and Control, the Chinese University of Hong Kong. 3. Division of Epidemiology, Department of Family Medicine and Public Health, School of Medicine, University of California.
Abstract
Introduction: Angiotensin II, a major effector protein of the renin angiotensin system (RAS), induces bone loss under certain conditions. Drugs that block the RAS may therefore reduce bone loss and fracture incidence. The fracture incidence in older hypertensive men with long-term use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) were compared with the incidence in users of calcium channel blockers (CCBs) and non-users. Methods: A total of 5,994 US men aged 65 years or older who had bone mineral density measured at baseline in the Osteoporotic Fractures in Men Study (MrOS) were followed for fracture incidence for an average of 6.8 years. Men with follow-up dual-energy X-ray absorptiometry bone mineral density data and who reported hypertension at any visit, or use of antihypertensive medications at any visit among those with non-missing mediation data were included in the study (N = 2,573). Results: Six hundred and nineteen men had taken ACE inhibitors, while 182 took ARBs for at least 4 years. Using Cox regression for the incidence of non-vertebral fractures, we found that long-term users of ACE inhibitors and ARBs each had a significantly lower fracture incidence than non-users. The hazard ratio of non-vertebral fractures was three times lower in ARB users than ACE inhibitor users (Hazard ratio (95% confidence interval): 0.194 (0.079–0.474) versus 0.620 (0.453–0.850), P = 0.0168). There was a trend of greater fracture risk reduction with longer duration of ARB use, but not for ACE inhibitor use. Conclusions: In older hypertensive men, ARBs use was associated with lower incidence of non-vertebral fracture than ACE inhibitors or CCBs.
Introduction: Angiotensin II, a major effector protein of the renin angiotensin system (RAS), induces bone loss under certain conditions. Drugs that block the RAS may therefore reduce bone loss and fracture incidence. The fracture incidence in older hypertensivemen with long-term use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) were compared with the incidence in users of calcium channel blockers (CCBs) and non-users. Methods: A total of 5,994 US men aged 65 years or older who had bone mineral density measured at baseline in the Osteoporotic Fractures in Men Study (MrOS) were followed for fracture incidence for an average of 6.8 years. Men with follow-up dual-energy X-ray absorptiometry bone mineral density data and who reported hypertension at any visit, or use of antihypertensive medications at any visit among those with non-missing mediation data were included in the study (N = 2,573). Results: Six hundred and nineteen men had taken ACE inhibitors, while 182 took ARBs for at least 4 years. Using Cox regression for the incidence of non-vertebral fractures, we found that long-term users of ACE inhibitors and ARBs each had a significantly lower fracture incidence than non-users. The hazard ratio of non-vertebral fractures was three times lower in ARB users than ACE inhibitor users (Hazard ratio (95% confidence interval): 0.194 (0.079–0.474) versus 0.620 (0.453–0.850), P = 0.0168). There was a trend of greater fracture risk reduction with longer duration of ARB use, but not for ACE inhibitor use. Conclusions: In older hypertensivemen, ARBs use was associated with lower incidence of non-vertebral fracture than ACE inhibitors or CCBs.
Authors: Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone Journal: Contemp Clin Trials Date: 2005-10 Impact factor: 2.226
Authors: Ya-feng Zhang; Ling Qin; Timothy C Y Kwok; Benson H Y Yeung; Guo-dong Li; Fan Liu Journal: Chin Med J (Engl) Date: 2013-07 Impact factor: 2.628
Authors: Lewis A Lipsitz; Daniel Habtemariam; Margaret Gagnon; Ikechukwu Iloputaife; Farzaneh Sorond; Achille E Tchalla; Thierry F Dantoine; Thomas G Travison Journal: Hypertension Date: 2015-05-04 Impact factor: 10.190
Authors: Joshua I Barzilay; Barry R Davis; Sara L Pressel; Alokananda Ghosh; Rachel Puttnam; Karen L Margolis; Paul K Whelton Journal: Curr Cardiol Rep Date: 2017-09 Impact factor: 2.931
Authors: L D Carbone; S Vasan; R L Prentice; G Harshfield; B Haring; J A Cauley; K C Johnson Journal: Osteoporos Int Date: 2019-06-17 Impact factor: 4.507
Authors: Kara L Holloway-Kew; Amelia G Betson; Kara B Anderson; James Gaston; Mark A Kotowicz; Wan-Hui Liao; Maciej Henneberg; Julie A Pasco Journal: Arch Osteoporos Date: 2021-09-18 Impact factor: 2.617
Authors: Setor K Kunutsor; Ashley W Blom; Michael R Whitehouse; Patrick G Kehoe; Jari A Laukkanen Journal: Eur J Epidemiol Date: 2017-07-27 Impact factor: 8.082
Authors: D Canoy; N C Harvey; D Prieto-Alhambra; C Cooper; H E Meyer; B O Åsvold; M Nazarzadeh; K Rahimi Journal: Osteoporos Int Date: 2021-10-13 Impact factor: 5.071
Authors: Alexander T Sandhu; Shun Kohsaka; Shoutzu Lin; Christopher Y Woo; Mary K Goldstein; Paul A Heidenreich Journal: Am Heart J Date: 2021-06-12 Impact factor: 4.749
Authors: Thais Francini Garbieri; Victor Martin; Carlos Ferreira Santos; Pedro de Sousa Gomes; Maria Helena Fernandes Journal: Pharmaceuticals (Basel) Date: 2021-05-16